- Package
- 1 g
- Purity
- 98%
- Price
- Request review
- Availability
- Shipping review required
- Delivery
- Shipping review required
CAS Number: 608141-41-9
Submit an RFQ to review pricing, availability, lead time, pack size, purity, COA, and supplier SDS for this catalog entry.
Available options
Shipping review is required before pricing or stock can be confirmed publicly. Shipping, duties, and documentation fees are confirmed before order acceptance.
CAS Number
608141-41-9
PubChem CID
11561674
Molecular Formula
C22H24N2O7S
Molecular Weight
460.5 g/mol
Exact Mass
460.130422
InChIKey
IMOZEMNVLZVGJZ-QGZVFWFLSA-N
IUPAC Name
N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]acetamide
SMILES String
CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC
pKa
12.58
Properties are provided as catalog reference data and may be confirmed through supplier documentation when required.
Structural features
Apremilast (CAS 608141-41-9) is listed in the Pharmaceutical Intermediates portfolio, with molecular formula C22H24N2O7S and molecular weight 460. 50 g/mol.
Sourcing context
Catalog reference for RFQ preparation, supplier confirmation, and research chemical sourcing review.
Research use context
Intended for research-stage medicinal chemistry and intermediate synthesis workflows; structure-derived tags include nitrogen-containing heterocycle.
Documentation needs
COA/SDS status, availability, lead time, pack size, and shipment documentation can be confirmed during quotation.
ChEMBL reports experimental activity evidence for: 3',5'-cyclic-AMP phosphodiesterase 4D (Homo sapiens) — 12 assays; 3',5'-cyclic-AMP phosphodiesterase 4B (Homo sapiens) — 6 assays; 5-hydroxytryptamine receptor 2B (Homo sapiens) — 2 assays; 3',5'-cyclic-AMP phosphodiesterase 4A (Homo sapiens) — 3 assays; 5-hydroxytryptamine receptor 1A (Homo sapiens) — 2 assays. These records describe research assays and do not establish therapeutic efficacy or clinical use.
3',5'-cyclic-AMP phosphodiesterase 4D
Homo sapiens · SINGLE PROTEIN · 12 qualifying assays · 11 documents · best pChEMBL 8.57
Experimental evidence source: ChEMBL
3',5'-cyclic-AMP phosphodiesterase 4B
Homo sapiens · SINGLE PROTEIN · 6 qualifying assays · 5 documents · best pChEMBL 7.78
Experimental evidence source: ChEMBL
5-hydroxytryptamine receptor 2B
Homo sapiens · SINGLE PROTEIN · 2 qualifying assays · 1 documents · best pChEMBL 5.35
Experimental evidence source: ChEMBL
3',5'-cyclic-AMP phosphodiesterase 4A
Homo sapiens · SINGLE PROTEIN · 3 qualifying assays · 1 documents
Experimental evidence source: ChEMBL
5-hydroxytryptamine receptor 1A
Homo sapiens · SINGLE PROTEIN · 2 qualifying assays · 1 documents
Experimental evidence source: ChEMBL
Safety and handling reference content is available through documentation requests.
For supplier-issued SDS, request documentation before handling, storage, shipment, or procurement decisions.
Preliminary Safety Reference
For supplier-issued SDS or COA, submit a documentation request.
Safety Reference / SDS RequestCatalog navigation
Other public CAS pages in this catalog. These links support navigation across additional intermediates and do not imply equivalence, availability, or shared use.
Apremilast is identified by CAS 608141-41-9, with molecular formula C22H24N2O7S, molecular weight 460.5, InChIKey IMOZEMNVLZVGJZ-QGZVFWFLSA-N.
ChEMBL contains qualifying experimental assay evidence associated with 3',5'-cyclic-AMP phosphodiesterase 4D, 3',5'-cyclic-AMP phosphodiesterase 4B, 5-hydroxytryptamine receptor 2B, 3',5'-cyclic-AMP phosphodiesterase 4A, 5-hydroxytryptamine receptor 1A. These records do not establish therapeutic efficacy or clinical use.
Yes. Submit an RFQ and specify COA requirements. Lot-specific COA depends on supplier confirmation.
Yes. Supplier SDS can be requested through the RFQ workflow before handling, storage, shipment, or procurement decisions.
Availability, pack size, lead time, and pricing are confirmed through RFQ.
Submit the CAS number, quantity, purity requirement, and destination country for sourcing review.